Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: recommendations from a Eastern and Southern Europe diabetes expert group
doi: 10.1007/s13300-020-00951-6 49 PackerMButlerJFilippatosGSJamalWSalsaliASchneeJet al
GLP-1 Weight Loss Provider Roundup: July 2025 Key Developments Whether youre already a busy GLP1 weight loss provider or just starting your journey with these therapies, you know that muscle preservation, tech-enabled care, insurance changes, and new treatment options are reshaping the field
A 2025 study published in AJMC found that many patients who stopped semaglutide or tirzepatide in real-world settings did not regain weight as rapidly as clinical trial outcomes suggested, particularly when tapering was gradual, and lifestyle support was in place
6 Challenges and future perspectives Despite the compelling preclinical evidence and promising early clinical results, the full translation of SFNs potential into reliable clinical applications faces several significant challenges
US$ 23.62
US$ 21.18
US$ 23.88
US$ 20.05
